CNI-free immunosuppression decreases the risk of malignancy after renal transplantation
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
Immunosuppression prolongs the survival of allograft recipients, but some immunosuppressants might also increase the risk of malignancy development in these patients. In experimental models, the calcineurin inhibitor (CNI) ciclosporin A (CsA) and the mTOR inhibitor sirolimus have tumor-promoting and tumor-inhibitory effects, respectively. A recent study investigated the effect of these drugs on the risk of renal transplant patients developing malignancies over a 5-year period.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
